Patent ID: 9539267
Date: 2017-01-10
CPC Classifications: A61K,A61P

Claim:
1. A method for eliminating or substantially reducing non-Hodgkin's lymphoma in a subject comprising administering a) a lymphocytotoxic but hematopoietic stem cell sparing high-dose pulsed amount of an oxazaphosphorine drug without combination chemotherapy, b) an effective amount of a monoclonal antibody consisting of a monoclonal antibody that selectively binds to a B-cell specific antigen and depletes or substantially reduces B cells to the subject, and not transplanting stem cells, such that the subject's immune system reconstitutes without stem cell transplantation, c) an effective amount of an autologous anti-idiotypic vaccine, d) an effective amount of a hematopoietic growth factor pegfilgrastin, and e) an effective amount of Mesna, thereby to eliminate or substantially reduce non-Hodgkin's lymphoma in the subject.